Apollo Endosurgery Seeks To Raise $31m In Share Sale
Executive Summary
Anti-obesity device company Apollo Endosurgery is looking to net around $31m through a sale of 5.7 million shares. The Austin, Texas-based company has seen slow sales in the last couple of years and is planning to use the funds to boost adoption of its endo-bariatric products, which includes the Orbera intragastric balloon and the Lap-Band gastric band which it inherited through acquiring Allergan’s obesity intervention division in 2013.
You may also be interested in...
Apollo Endosurgery Inflates Coffers With $36m
Anti-obesity device company Apollo Endosurgery has closed a $36m share offering.
US FDA Warns Docs On Gastric Balloon Adverse Events
Gastric balloons from ReShape Medical and Apollo Endosurgery have been tied to pancreatitis and problems caused by over-inflation, the agency says.
Two Indicted For Sales Of Expired Lap-Band Devices
Two former sales executives at Apollo Endo-Surgery were indicted Dec. 8 in Florida on charges that they fraudulently relabeled and resold expired Lap-Band gastric surgery devices.